Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Reiter

Showing results (71-80 of 211) with videos related to

Pageof 22
Sort By:
Leukemia|November 18, 2025
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genesMatthew Salmon, Nicole Naumann, Jenny Rinke, et al.
Leukemia|July 15, 2023
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohortGeorgia Metzgeroth, Laurenz Steiner, Nicole Naumann, et al.
Annals of Hematology|January 31, 2025
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024Martin Griesshammer, Haifa Kathrin Al-Ali, Jan-Niklas Eckardt, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 12, 2021
Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosisJuliana Schwaab, Knut Brockow, Philipp Riffel, et al.
Cancer Genetics|January 19, 2023
Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in childrenAnn-Cathrine Berking, Tim Flaadt, Yvonne Lisa Behrens, et al.
British Journal of Haematology|October 28, 2008
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II studyGeorgia Metzgeroth, Christoph Walz, Philipp Erben, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Pageof 22

Showing results (71-80 of 211) with videos related to

Sort By:
Pageof 22
Leukemia|November 18, 2025
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genesMatthew Salmon, Nicole Naumann, Jenny Rinke, et al.
Leukemia|July 15, 2023
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohortGeorgia Metzgeroth, Laurenz Steiner, Nicole Naumann, et al.
Annals of Hematology|January 31, 2025
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024Martin Griesshammer, Haifa Kathrin Al-Ali, Jan-Niklas Eckardt, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|October 12, 2021
Low risk of contrast media-induced hypersensitivity reactions in all subtypes of systemic mastocytosisJuliana Schwaab, Knut Brockow, Philipp Riffel, et al.
Cancer Genetics|January 19, 2023
Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in childrenAnn-Cathrine Berking, Tim Flaadt, Yvonne Lisa Behrens, et al.
British Journal of Haematology|October 28, 2008
Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II studyGeorgia Metzgeroth, Christoph Walz, Philipp Erben, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Pageof 22